ORY — ORYZON Genomics SA Cashflow Statement
0.000.00%
Last trade - 00:00- €121.81m
- €125.56m
- 21
- 32
- 54
- 25
Annual cashflow statement for ORYZON Genomics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.58 | -4.78 | -7.18 | -6.56 | -6.1 |
| Depreciation | |||||
| Non-Cash Items | 0.559 | 0.425 | 0.23 | 1.11 | 1.84 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.067 | -0.609 | 3.18 | 3.43 | 3.54 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -3.93 | -4.82 | -3.63 | -1.85 | -0.575 |
| Capital Expenditures | -9.58 | -9.22 | -11.8 | -14.3 | -14.5 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.008 | 0.142 | 0.037 | -0.001 | -0.001 |
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -9.58 | -9.08 | -11.7 | -14.3 | -14.5 |
| Financing Cash Flow Items | 0.079 | 0.226 | 0 | 0.144 | 0.076 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 14.3 | 18.4 | 4.12 | 8.71 | 6.02 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.791 | 4.49 | -10.9 | -7.41 | -9.06 |